SBIR/STTR Research Award

A NEW GENERATION OF BOTULINUM TOXIN VACCINES

Award identifier 3aae840cbe470814b6e1583a4bc85b05fa81336706a802e8dd32e8e6c20fd830Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,800

Program and phase

SBIR · Phase I

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INVENTOX INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Botulinum toxin is a potential bioweapon that can be used in acts of bioterrorism or biological warfare. Although the toxin is extraordinarily potent, there is little likelihood that there will be universal vaccination of the public. This can be attributed to two facts: a.) the perceived risk associated with use of the toxin as a bioweapon does not, at the present time, warrant universal vaccination, and b.) the toxin is a therapeutic agent for the treatment of neurologic, neuro-opthalmologic and related disorders, and universal vaccination would deprive patients who may need these therapeutic benefits. However, there are certain populations in whom vaccination would be warranted. These range from health care workers who may be first responders to members of the military services assigned to areas where there could be bioweapons. The goal of the proposed research is to develop a modern vaccine that will meet the needs of these vulnerable populations. This will be accomplished by pursuing three goals, each of which represents a significant improvement over current vaccine technology. First, site-directed mutagenesis will be used to create novel vaccine candidates that do not bind to cholinergic nerve endings, and therefore cannot evoke adverse neurologic side effects. Second, fusion genes will be constructed that will permit expression of chimeric polypeptides that are multivalent, non-neurotropic vaccines against two of the botulinum toxin serotypes (A, B) that pose the greatest threat to human health. Third, non-neurotropic multivalent constructs will be tested as mucosal vaccines that will evoke secretory antibodies that will block toxin absorption into the body. In the aggregate, these three advancements will lead to botulinum toxin vaccine that is superior to any other product that has been described. PUBLIC HEALTH RELEVANCE: Botulinum toxin is a microbial agent that causes the disease botulism. Naturally occurring botulism is not common, and thus there is no need for universal vaccination. However, botulism that is the product of bioterrorism or biological warfare could pose a high risk to certain populations, ranging from health care workers to members of the military, and these select populations may need access to a vaccine. Therefore, the goal of the proposed work is to develop a mucosal vaccine that will protect vulnerable populations against the use of botulinum toxin as a bioweapon.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.